

CHLD0071: Molecular and Clinical Aspects of Childhood Cancers

View Online



Azarova, A. M., Gautam, G., & George, R. E. (2011). Emerging importance of ALK in neuroblastoma. *Seminars in Cancer Biology*, 21(4), 267–275. <https://doi.org/10.1016/j.semcancer.2011.09.005>

Beierle, E. A. (n.d.). MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK). *Frontiers in Bioscience (Elite Edition)*, 3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/>

Bell, E., Chen, L., Liu, T., Marshall, G. M., Lunec, J., & Tweddle, D. A. (2010). MYCN oncoprotein targets and their therapeutic potential. *Cancer Letters*, 293(2), 144–157. <https://doi.org/10.1016/j.canlet.2010.01.015>

Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., Radlwimmer, B., Højfeldt, J. W., Truffaux, N., Castel, D., Schubert, S., Ryzhova, M., Şeker-Cin, H., Gronych, J., Johann, P. D., ... Pfister, S. M. (2013). Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. *Cancer Cell*, 24(5), 660–672. <https://doi.org/10.1016/j.ccr.2013.10.006>

Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., Ahmad, Z., Barker, K., Moreau, L., Webber, H., Wang, W., Liu, Q., Perez-Atayde, A., Rodig, S., Cheung, N.-K., ... George, R. E. (2012). The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. *Cancer Cell*, 22(1), 117–130. <https://doi.org/10.1016/j.ccr.2012.06.001>

Bleggi-Torres, L. F., de Noronha, L., Schneider Gugelmin, E., Martins Sebastião, A. P., Werner, B., Marques Maggio, E., Queiroz Telles, J. E., & Martins Collaço, L. (2001). Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system. *Diagnostic Cytopathology*, 24(4), 293–295. <https://doi.org/10.1002/dc.1062>

Blümcke, I., Aronica, E., Becker, A., Capper, D., Coras, R., Honavar, M., Jacques, T. S., Kobow, K., Miyata, H., Mühlebner, A., Pimentel, J., Söylemezoğlu, F., & Thom, M. (2016). Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification. *Nature Reviews Neurology*, 12(12), 732–740. <https://doi.org/10.1038/nrneuro.2016.173>

Brodeur, G. M. (2003). Neuroblastoma: biological insights into a clinical enigma. *Nature Reviews Cancer*, 3(3), 203–216. <https://doi.org/10.1038/nrc1014>

Brodeur, G. M., & Bagatell, R. (2014). Mechanisms of neuroblastoma regression. *Nature Reviews Clinical Oncology*, 11(12), 704–713. <https://doi.org/10.1038/nrclinonc.2014.168>

- Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., Kurien, A., Priceman, S. J., Wang, X., Harshbarger, T. L., D'Apuzzo, M., Ressler, J. A., Jensen, M. C., Barish, M. E., Chen, M., ... Badie, B. (2016). Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. *New England Journal of Medicine*, 375(26), 2561–2569. <https://doi.org/10.1056/NEJMoa1610497>
- Buckner, T., Blatt, J., & Smith, S. V. (2006). The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience. *Pediatric and Developmental Pathology*, 9(5), 374–380. <https://doi.org/10.2350/06-02-0047.1>
- Burkhart, C. A., Cheng, A. J., Madafiglio, J., Kavallaris, M., Mili, M., Marshall, G. M., Weiss, W. A., Khachigian, L. M., Norris, M. D., & Haber, M. (2003). Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. *JNCI Journal of the National Cancer Institute*, 95(18), 1394–1403. <https://doi.org/10.1093/jnci/djg045>
- Chen, L., Iraci, N., Gherardi, S., Gamble, L. D., Wood, K. M., Perini, G., Lunec, J., & Tweddle, D. A. (2010). p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma. *Cancer Research*, 70(4), 1377–1388. <https://doi.org/10.1158/0008-5472.CAN-09-2598>
- Chhabda, S., Carney, O., D'Arco, F., Jacques, T. S., & Mankad, K. (2016). The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know. *Quantitative Imaging in Medicine and Surgery*, 6(5), 486–489. <https://doi.org/10.21037/qims.2016.10.01>
- Children's cancer statistics | Cancer Research UK. (n.d.). <http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>
- Cossu, I., Bottoni, G., Loi, M., Emionite, L., Bartolini, A., Di Paolo, D., Brignole, C., Piaggio, F., Perri, P., Sacchi, A., Curnis, F., Gagliani, M. C., Bruno, S., Marini, C., Gori, A., Longhi, R., Murgia, D., Sementa, A. R., Cilli, M., ... Pastorino, F. (2015). Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. *Biomaterials*, 68, 89–99. <https://doi.org/10.1016/j.biomaterials.2015.07.054>
- Ellison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D., & Clifford, S. C. (2005). β -Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. *Journal of Clinical Oncology*, 23(31), 7951–7957. <https://doi.org/10.1200/JCO.2005.01.5479>
- Evans, A. E., Baum, E., & Chard, R. (1981). Do infants with stage IV-S neuroblastoma need treatment? *Archives of Disease in Childhood*, 56(4), 271–274. <https://doi.org/10.1136/adc.56.4.271>
- Fisher, J., Abramowski, P., Wisidagamage Don, N. D., Flutter, B., Capsomidis, A., Cheung, G. W.-K., Gustafsson, K., & Anderson, J. (2017). Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. *Molecular Therapy*, 25(5), 1234–1247. <https://doi.org/10.1016/j.ymthe.2017.03.002>

- Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop. (1984). Amplification of N-myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage. *Science*, 224(4653), 1121-1124.
<http://www.jstor.org/stable/1692440>
- Ghorashian, S., Amrolia, P., & Veys, P. (2018). Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL. *Experimental Hematology*, 66, 5-16.
<https://doi.org/10.1016/j.exphem.2018.07.002>
- Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., Finkelstein, D., Pounds, S., Weiss, A., Patay, Z., Scoggins, M., Ogg, R., Pei, Y., Yang, Z.-J., Brun, S., ... Gilbertson, R. J. (2010). Subtypes of medulloblastoma have distinct developmental origins. *Nature*, 468(7327), 1095-1099.
<https://doi.org/10.1038/nature09587>
- Goschzik, T., Gessi, M., Dreschmann, V., Gebhardt, U., Wang, L., Yamaguchi, S., Wheeler, D. A., Lauriola, L., Lau, C. C., Müller, H. L., & Pietsch, T. (2017). Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. *Journal of Neuropathology & Experimental Neurology*. <https://doi.org/10.1093/jnen/nlw116>
- Greaves, M. F., & Wiemels, J. (2003). Origins of chromosome translocations in childhood leukaemia. *Nature Reviews Cancer*, 3(9), 639-649. <https://doi.org/10.1038/nrc1164>
- Guglielmi, L., Cinnella, C., Nardella, M., Maresca, G., Valentini, A., Mercanti, D., Felsani, A., & D'Agnano, I. (2014). MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells. *Cell Death & Disease*, 5(2), e1081-e1081. <https://doi.org/10.1038/cddis.2014.42>
- Gump, J. M., Donson, A. M., Birks, D. K., Amani, V. M., Rao, K. K., Griesinger, A. M., Kleinschmidt-DeMasters, B. K., Johnston, J. M., Anderson, R. C. E., Rosenfeld, A., Handler, M., Gore, L., Foreman, N., & Hankinson, T. C. (2015). Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. *Acta Neuropathologica Communications*, 3(1). <https://doi.org/10.1186/s40478-015-0211-5>
- Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. *Cell*, 100(1), 57-70.
[https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9)
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. *Cell*, 144(5), 646-674. <https://doi.org/10.1016/j.cell.2011.02.013>
- Hashizume, R., Andor, N., Ihara, Y., Lerner, R., Gan, H., Chen, X., Fang, D., Huang, X., Tom, M. W., Ngo, V., Solomon, D., Mueller, S., Paris, P. L., Zhang, Z., Petritsch, C., Gupta, N., Waldman, T. A., & James, C. D. (2014). Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. *Nature Medicine*, 20(12), 1394-1396.
<https://doi.org/10.1038/nm.3716>
- Hasle, H., & Niemeyer, C. M. (2011). Advances in the prognostication and management of advanced MDS in children. *British Journal of Haematology*, 154(2), 185-195.
<https://doi.org/10.1111/j.1365-2141.2011.08724.x>
- Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boulton, J. K. R.,

Williamson, D., Ahmad, Z., Hallsworth, A., Ryan, S. L., Poon, E., Robinson, S. P., Ruddle, R., Raynaud, F. I., Howell, L., Kwok, C., Joshi, A., Nicholson, S. L., ... Clifford, S. C. (2015). Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. *Cancer Cell*, 27(1), 72–84. <https://doi.org/10.1016/j.ccell.2014.11.002>

Hourigan, C. S., & Karp, J. E. (2013). Minimal residual disease in acute myeloid leukaemia. *Nature Reviews Clinical Oncology*, 10(8), 460–471. <https://doi.org/10.1038/nrclinonc.2013.100>

Huang, M., & Weiss, W. A. (2013). Neuroblastoma and MYCN. *Cold Spring Harbor Perspectives in Medicine*, 3(10), a014415–a014415. <https://doi.org/10.1101/cshperspect.a014415>

Huber, K., Kalcheim, C., & Unsicker, K. (2009). The development of the chromaffin cell lineage from the neural crest. *Autonomic Neuroscience*, 151(1), 10–16. <https://doi.org/10.1016/j.autneu.2009.07.020>

Hubert, C. G., Rivera, M., Spangler, L. C., Wu, Q., Mack, S. C., Prager, B. C., Couce, M., McLendon, R. E., Sloan, A. E., & Rich, J. N. (2016). A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found. *Cancer Research*, 76(8), 2465–2477. <https://doi.org/10.1158/0008-5472.CAN-15-2402>

Hunger, S. P., & Mullighan, C. G. (2015). Acute Lymphoblastic Leukemia in Children. *New England Journal of Medicine*, 373(16), 1541–1552. <https://doi.org/10.1056/NEJMra1400972>

International Agency for Research on Cancer. (2016). WHO classification of tumours of the central nervous system (D. N. Louis, H. Ohgaki, O. D. Wiestler, & W. K. Cavenee, Eds.; Revised 4th edition). International Agency for Research on Cancer.

Johnson, L. A., & June, C. H. (2017). Driving gene-engineered T cell immunotherapy of cancer. *Cell Research*, 27(1), 38–58. <https://doi.org/10.1038/cr.2016.154>

Kirsti Sirkiä, Ulla M. Saarinen-Pihkala, Liisa Hovi, Hannu Sariola. (1998). Autopsy in children with cancer who die while in terminal care. *Medical and Pediatric Oncology*, 30(5), 284–289. [https://doi.org/10.1002/\(SICI\)1096-911X\(199805\)30:5<284::AID-MPO4>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B)

Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016). Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine*, 22(1), 26–36. <https://doi.org/10.1038/nm.4015>

Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. *Nature*, 450(7171), 903–907. <https://doi.org/10.1038/nature06309>

Korshunov, Andrey Sturm, Dominik Ryzhova, Marina Hovestadt, Volker Gessi, Marco. (n.d.). Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single

clinicopathological entity. *Acta Neuropathologica*, 128(8), 279–289.
<https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&aaccountid=14511>

Kotrova, M., Trka, J., Kneba, M., & Brüggemann, M. (2017). Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia? *Molecular Diagnosis & Therapy*, 21(5), 481–492.
<https://doi.org/10.1007/s40291-017-0277-9>

Larson, J. D., Kasper, L. H., Paugh, B. S., Jin, H., Wu, G., Kwon, C.-H., Fan, Y., Shaw, T. I., Silveira, A. B., Qu, C., Xu, R., Zhu, X., Zhang, J., Russell, H. R., Peters, J. L., Finkelstein, D., Xu, B., Lin, T., Tinkle, C. L., ... Baker, S. J. (2018). Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. *Cancer Cell*. <https://doi.org/10.1016/j.ccell.2018.11.015>

Lee, T. I., & Young, R. A. (2013). Transcriptional Regulation and Its Misregulation in Disease. *Cell*, 152(6), 1237–1251. <https://doi.org/10.1016/j.cell.2013.02.014>

Lewis, P. W., Muller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013). Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma. *Science*, 340(6134), 857–861. <https://doi.org/10.1126/science.1232245>

Liu, Z., & Thiele, C. J. (2012). ALK and MYCN: When Two Oncogenes Are Better than One. *Cancer Cell*, 21(3), 325–326. <https://doi.org/10.1016/j.ccr.2012.03.004>

Lord, C. J., & Ashworth, A. (2010). Biology-driven cancer drug development: back to the future. *BMC Biology*, 8(1). <https://doi.org/10.1186/1741-7007-8-38>

Lu, B., Green, B., Farr, J., Lopes, F., & Van Raay, T. (2016). Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. *Cancers*, 8(9).
<https://doi.org/10.3390/cancers8090082>

Mackall, C. L., Merchant, M. S., & Fry, T. J. (2014). Immune-based therapies for childhood cancer. *Nature Reviews Clinical Oncology*, 11(12), 693–703.
<https://doi.org/10.1038/nrclinonc.2014.177>

Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017). Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. *Cancer Cell*, 31(4), 476–485.
<https://doi.org/10.1016/j.ccell.2017.03.002>

Marabelle, A., Sapin, V., Rousseau, R., Periquet, B., Demeocq, F., & Kanold, J. (2009). Hypercalcemia and 13-*cis*-retinoic acid in post-consolidation therapy of neuroblastoma. *Pediatric Blood & Cancer*, 52(2), 280–283.
<https://doi.org/10.1002/pbc.21768>

Martinez-Barbera, J. P., & Andoniadou, C. L. (2016). Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma. *STEM CELLS*, 34(2), 268–276. <https://doi.org/10.1002/stem.2267>

Martinez-Barbera, J. P., & Buslei, R. (2015). Adamantinomatous craniopharyngioma:

pathology, molecular genetics and mouse models. *Journal of Pediatric Endocrinology and Metabolism*, 28(1-2). <https://doi.org/10.1515/jpem-2014-0442>

Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., Gerbing, R. B., & Reynolds, C. P. (1999). Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-*cis*-Retinoic Acid. *New England Journal of Medicine*, 341(16), 1165–1173. <https://doi.org/10.1056/NEJM199910143411601>

Milne, T. A. (2017). Mouse models of MLL leukemia: recapitulating the human disease. *Blood*, 129(16), 2217–2223. <https://doi.org/10.1182/blood-2016-10-691428>

Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016). Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. *Cell*, 164(4), 780–791. <https://doi.org/10.1016/j.cell.2016.01.012>

Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., Laureys, G., Speleman, F., Kim, C., Hou, C., Hakonarson, H., Torkamani, A., Schork, N. J., Brodeur, G. M., Tonini, G. P., ... Maris, J. M. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature*, 455(7215), 930–935. <https://doi.org/10.1038/nature07261>

Nataliya Zhukova. (2013). Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. *Journal of Clinical Oncology*, 31(23). <https://doi.org/10.1200/JCO.2012.48.5052>

Nature Reviews Immunology. (2012). 12(4). <https://www.nature.com/nri/volumes/12/issues/4>

Niemeyer, C. M., & Kratz, C. P. (2008). Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. *British Journal of Haematology*, 140(6), 610–624. <https://doi.org/10.1111/j.1365-2141.2007.06958.x>

Niklison-Chirou, M. V., Erngren, I., Engskog, M., Haglöf, J., Picard, D., Remke, M., McPolin, P. H. R., Selby, M., Williamson, D., Clifford, S. C., Michod, D., Hadjiandreou, M., Arvidsson, T., Pettersson, C., Melino, G., & Marino, S. (2017). TAp73 is a marker of glutamine addiction in medulloblastoma. *Genes & Development*, 31(17), 1738–1753. <https://doi.org/10.1101/gad.302349.117>

Northcott, P. A., Korshunov, A., Pfister, S. M., & Taylor, M. D. (2012). The clinical implications of medulloblastoma subgroups. *Nature Reviews Neurology*, 8(6), 340–351. <https://doi.org/10.1038/nrneurol.2012.78>

O'Connor, D., Enshaei, A., Bartram, J., Hancock, J., Harrison, C. J., Hough, R., Samarasinghe, S., Schwab, C., Vora, A., Wade, R., Moppett, J., Moorman, A. V., & Goulden, N. (2018a). Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, 36(1), 34–43. <https://doi.org/10.1200/JCO.2017.74.0449>

O'Connor, D., Enshaei, A., Bartram, J., Hancock, J., Harrison, C. J., Hough, R., Samarasinghe,

- S., Schwab, C., Vora, A., Wade, R., Moppett, J., Moorman, A. V., & Goulden, N. (2018b). Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, 36(1), 34–43. <https://doi.org/10.1200/JCO.2017.74.0449>
- Pastorino, F., Marimpietri, D., Brignole, C., Paolo, D., Pagnan, G., Daga, A., Piccardi, F., Cilli, M., Allen, T., & Ponzoni, M. (2007). Ligand-Targeted Liposomal Therapies of Neuroblastoma. *Current Medicinal Chemistry*, 14(29), 3070–3078. <https://doi.org/10.2174/092986707782793916>
- Pathania, M., De Jay, N., Maestro, N., Harutyunyan, A. S., Nitarska, J., Pahlavan, P., Henderson, S., Mikael, L. G., Richard-Londt, A., Zhang, Y., Costa, J. R., Hébert, S., Khazaei, S., Ibrahim, N. S., Herrero, J., Riccio, A., Albrecht, S., Ketteler, R., Brandner, S., ... Salomoni, P. (2017). H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. *Cancer Cell*, 32(5), 684–700.e9. <https://doi.org/10.1016/j.ccell.2017.09.014>
- Pfister, S., Remke, M., Castoldi, M., Bai, A. H. C., Muckenthaler, M. U., Kulozik, A., von Deimling, A., Pscherer, A., Lichter, P., & Korshunov, A. (2009). Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. *Acta Neuropathologica*, 117(4), 457–464. <https://doi.org/10.1007/s00401-008-0467-y>
- Phoenix, T. N., Patmore, D. M., Boop, S., Boulos, N., Jacus, M. O., Patel, Y. T., Roussel, M. F., Finkelstein, D., Goumnerova, L., Perreault, S., Wadhwa, E., Cho, Y.-J., Stewart, C. F., & Gilbertson, R. J. (2016). Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. *Cancer Cell*, 29(4), 508–522. <https://doi.org/10.1016/j.ccell.2016.03.002>
- Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., Ghorashian, S., Pinner, D., Ahsan, G., Gilmour, K., Lucchini, G., Inglott, S., Mifsud, W., Chiesa, R., Peggs, K. S., ... Veys, P. (2017). Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Science Translational Medicine*, 9(374). <https://doi.org/10.1126/scitranslmed.aaj2013>
- Qiao, J., Paul, P., Lee, S., Qiao, L., Josifi, E., Tiao, J. R., & Chung, D. H. (2012). PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. *Biochemical and Biophysical Research Communications*, 424(3), 421–426. <https://doi.org/10.1016/j.bbrc.2012.06.125>
- Rasaiyaah, J., Georgiadis, C., Preece, R., Mock, U., & Qasim, W. (2018). TCR $\alpha\beta$ /CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. *JCI Insight*, 3(13). <https://doi.org/10.1172/jci.insight.99442>
- Reynolds, C. P., Matthay, K. K., Villablanca, J. G., & Maurer, B. J. (2003). Retinoid therapy of high-risk neuroblastoma. *Cancer Letters*, 197(1–2), 185–192. [https://doi.org/10.1016/S0304-3835\(03\)00108-3](https://doi.org/10.1016/S0304-3835(03)00108-3)
- Richmond, A., & Su, Y. (2008). Mouse xenograft models vs GEM models for human cancer therapeutics. *Disease Models and Mechanisms*, 1(2–3), 78–82. <https://doi.org/10.1242/dmm.000976>

- Sadelain, M., Rivière, I., & Riddell, S. (2017). Therapeutic T cell engineering. *Nature*, 545 (7655), 423–431. <https://doi.org/10.1038/nature22395>
- Schwab, M. (2004). MYCN in neuronal tumours. *Cancer Letters*, 204(2), 179–187. [https://doi.org/10.1016/S0304-3835\(03\)00454-3](https://doi.org/10.1016/S0304-3835(03)00454-3)
- Schwalbe, E. C., Lindsey, J. C., Nakjang, S., Crosier, S., Smith, A. J., Hicks, D., Rafiee, G., Hill, R. M., Iliasova, A., Stone, T., Pizer, B., Michalski, A., Joshi, A., Wharton, S. B., Jacques, T. S., Bailey, S., Williamson, D., & Clifford, S. C. (2017). Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. *The Lancet Oncology*, 18(7), 958–971. [https://doi.org/10.1016/S1470-2045\(17\)30243-7](https://doi.org/10.1016/S1470-2045(17)30243-7)
- Schwalbe, E. C., Hayden, J. T., Rogers, H. A., Miller, S., Lindsey, J. C., Hill, R. M., Nicholson, S.-L., Kilday, J.-P., Adamowicz-Brice, M., Storer, L., Jacques, T. S., Robson, K., Lowe, J., Williamson, D., Grundy, R. G., Bailey, S., & Clifford, S. C. (2013). Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. *Acta Neuropathologica*, 126(6), 943–946. <https://doi.org/10.1007/s00401-013-1206-6>
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., ... Collins, V. P. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*, 482(7384), 226–231. <https://doi.org/10.1038/nature10833>
- Sidell, N. (1982). Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro. *JNCI: Journal of the National Cancer Institute*. <https://doi.org/10.1093/jnci/68.4.589>
- Slany, R. K. (2016). The molecular mechanics of mixed lineage leukemia. *Oncogene*, 35 (40), 5215–5223. <https://doi.org/10.1038/onc.2016.30>
- Stone, T. J., & Jacques, T. S. (2015). Medulloblastoma: selecting children for reduced treatment. *Neuropathology and Applied Neurobiology*, 41(2), 106–108. <https://doi.org/10.1111/nan.12193>
- Strebhardt, K., & Ullrich, A. (2008). Paul Ehrlich's magic bullet concept: 100 years of progress. *Nature Reviews Cancer*, 8(6), 473–480. <https://doi.org/10.1038/nrc2394>
- Sturm, D., Orr, B. A., Toprak, U. H., Hovestadt, V., Jones, D. T. W., Capper, D., Sill, M., Buchhalter, I., Northcott, P. A., Leis, I., Ryzhova, M., Koelsche, C., Pfaff, E., Allen, S. J., Balasubramanian, G., Worst, B. C., Pajtler, K. W., Brabetz, S., Johann, P. D., ... Schniederjan, M. J. (2016). New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, 164(5), 1060–1072. <https://doi.org/10.1016/j.cell.2016.01.015>
- Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., Kool, M., Zapatka, M., Becker, N., Zucknick, M., Hielscher, T., Liu, X.-Y., Fontebasso, A. M., Ryzhova, M., Albrecht, S., ... Witt, O. (2012). Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups

of Glioblastoma. *Cancer Cell*, 22(4), 425–437. <https://doi.org/10.1016/j.ccr.2012.08.024>

Taylor, Michael D Northcott, Paul A Korshunov, Andrey Remke, Marc Cho, Yoon-jae. (n.d.). Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathologica*, 123(3), 465–472.
https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprim

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013a). Cancer Genome Landscapes. *Science*, 339(6127), 1546–1558.
<https://doi.org/10.1126/science.1235122>

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013b). Cancer Genome Landscapes. *Science*, 339(6127), 1546–1558.
<https://doi.org/10.1126/science.1235122>

Vora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Moorman, A. V., & Wade, R. (2014). Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. *The Lancet Oncology*, 15(8), 809–818.
[https://doi.org/10.1016/S1470-2045\(14\)70243-8](https://doi.org/10.1016/S1470-2045(14)70243-8)

Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013). Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. *The Lancet Oncology*, 14(3), 199–209.
[https://doi.org/10.1016/S1470-2045\(12\)70600-9](https://doi.org/10.1016/S1470-2045(12)70600-9)

Wegman-Ostrosky, T., & Savage, S. A. (2017). The genomics of inherited bone marrow failure: from mechanism to the clinic. *British Journal of Haematology*, 177(4), 526–542.
<https://doi.org/10.1111/bjh.14535>

Weinberg, R. A. (2014). *The biology of cancer* (2nd ed). Garland Science.

Wright, J. H. (1910). NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED. *The Journal of Experimental Medicine*, 12(4).
<https://doi.org/10.1084/jem.12.4.556>

Yang, Liqun Ke, Xiao-Xue Xuan, Fan Tan, Juan Hou, Jianbing. (n.d.). PHOX2B Is Associated with Neuroblastoma Cell Differentiation. *Cancer Biotherapy & Radiopharmaceuticals*, 31, 44–51. <https://doi.org/10.1089/cbr.2015.1952>

Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. (2017). CAR T-cell therapy of solid tumors. *Immunology and Cell Biology*, 95(4), 356–363.
<https://doi.org/10.1038/icb.2016.128>

Zelent, A., Greaves, M., & Enver, T. (2004). Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. *Oncogene*, 23(24), 4275–4283. <https://doi.org/10.1038/sj.onc.1207672>

Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D.

S., Helman, D., Feng, H., Stewart, R. A., Wang, W., George, R. E., Kanki, J. P., & Look, A. T. (2012). Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. *Cancer Cell*, 21(3), 362–373. <https://doi.org/10.1016/j.ccr.2012.02.010>